Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obizur in Congenital Hemophilia A with Inhibitors Undergoing Surgery
NCT02895945Phase 3Terminated
- Sponsor
- Takeda
- Start
- Dec 2016
- Primary completion
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
A Phase 3 trial of susoctocog alfa in hemophilia A, sponsored by Takeda. Started Dec 2016; status: terminated.
02
Drugs
susoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02895945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02895945.